Local hormonal factors (Intracrine, autocrine, and paracrine) in hypertension

Hypertension

Volumn 18, Issue 3, 1991, Pages I-58-I-69

  Carretero, Oscar A ^a   Guillermo Sdcti, A ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II; Blood pressure; Hormones; Kinins; Neutral endopeptidase 24.11; Rennin

Indexed keywords

VASOACTIVE AGENT;

CONFERENCE PAPER; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

ANGIOTENSIN II; ANIMAL; BLOOD PRESSURE; HORMONES; HUMAN; HYPERTENSION; KININS; PROTEASE INHIBITORS; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0025913709     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: None     Document Type: Article

References (120)

1. Owens GK: Control of hypertrophic versus hyperplastic growth of vascular smooth musde cells. Am J Physio! 1989; 257:H1755-H1765
2. Ferrario CM, Page IH: Current views concerning cardiac output in ihe genesis of experimental hypertension. Circ Res 1978;43:821-831
3. Zandtetti A; Volhard Lecture: Sympatho-renal interactions and blood pressure control. J Hypenens 1986;4 (suppl)S4-S13
4. Carretero OA, Scicii AG: Kinins paracrine hormone. Kidney Int 1988;34(suppl 26):S-52-S-59
5. Sybertz EJ Jr, Chiu PJS, Watkins RW, Vemulapalli S; Neutral metalloendopeptidase inhibition: A novel means of circulatory modulation. J Hypertens 1990;8(suppl 7):S161-S167
6. Seymour AA, Norman JA, Asaad MM, Fennell SA, Swerdel JN, Little DK, Dorso CR: Renal and depressor effects of SQ 29, 072, a neutral endopeptidase inhibitor, in conscious hypertensive rats. J Cardiovasc Pharmacol 1990;16:163-172
7. Genden EM, Molineaiu CJ: Inhibition of endopeptidase-24.15 decreases blood pressure in normotensive rats. Hypertension (in press)
8. Ferrario CM, Barnes KL, Block CH, Brosnihan KB, Diz Dl, Khosla MC, Santos RAS: Pathways of angiotensin formation and function in the brain. Hypertension 1990;15(suppl I): I-13-1-19
9. Gould AB, Skeggs LT Jr, Kahn JR: The presence of renin activity in blood vessel walls. J Exp Med 1964;119:389-399
10. Mulrow PJ: Adrenal renin: A possible local regulator of aldosterone production. Yale J Biol Med 1989;62:503-510
11. Gross F, Schaechtelin G, Ziegler M, Berger M: A renin-like substance in the placenta and uterus of the rabbit. Lancet 1964;1:914-916
12. Bumpus FM, Pucell AG, Daud Al, Husain A: Angiotensin II: An intraovarian regulatory peptide. Am J Med Sci 1988;31: 406-408
13. Carretero OA, Bujak B, Houle JA: Renin isozymes of extra renal origin. Am J Physiol 1971;220:1468-1472
14. Bing J, Faarup P: Location and site of formation of extrare-nal renin. Exp Sci Fran Pahs 1965;1:75-84
15. Okamura T, Clemens DL, Inagami T: Renin, angiotensins, and angiotensin-converting enzyme in neuroblastoma cells: Evidence for intracellular formation of angiotensins. Proc Natl Acad Sci U S A 1981;78:6940-6943
16. Pandey KN, Inagami T: Regulation of renin-angiotensins by gonadotropic hormones in cultured Leydig tumor cells: Release of angiotensin but not renin. J Biol Chem 1986;261: 3934-3938
17. Okamura T, Clemens DL, Inagami T: Generation of angiotensins in cultured pheochromocytoma cells. Neurosci Lett 1984;46:151-156
18. Kifor I, Dzau VJ: Endothelial renin-angiotensin pathway Evidence for intracellular synthesis and secretion of angiotensins. Circ Res 1987;60:422-428
19. Inagami T, Mizuno K, Naruse K, Okamura T, Ka warn ura M: Intracellular formation and release of angiotensins from juxtaglomerular cells. Kidney Ini 1990;38(suppl 30):S33-S37
20. Mizuno K, Niimura S, Tani M, Fukuchi S, Inagami T: Effect of delapril hydrochloride on angiotensin II release from isolated rat hind legs. Eur J Pharmacol 1990;184:169-172
21. Boucher R, Demassieui S, Garcia R, Genest J: Tonin, angiotensin II system. Circ Res 1977;41:26-29
22. Weintroub BT Klickstein LB, Dzau VJ, Watt KWK: Granulocyte-a ngiotensin system. Identification of angiotensinogen as substrate of leukocyte cathepsin G, Biochemistry 1984, 23: 227-232
23. Tang SS, Loscalzo J, Dzau VJ: Tissue plasminogen activator activates renin angiotensin in vitro. J Vase Med Biol 1989;1: 67-74
24. Okunishi H, Myazaki M, Toda N: Evidence for a putatively new angiotensin 11-generating enzyme in The vascular wall. J Hypertens 1934;2:277-284
25. Yamaguchi T, Carretero OA, Scicli AG: A potent vasoconstrictor in the rat submandibular gland. Hypertension 1991;17: 101-106
26. Yamaguchi T, Carretero OA, Scicli AG: A novel serine protease with vasoconstrictor activity coded by the kallikrein gene S3. J BioI Chem 1991;266:5011-5017
27. Kbairallah PA, Robertson AL, Davila D: Effects of angiotensin II on DNA, RNA and protein synthesis, in Genest J, Koiw E (eds): Hypertension (72). New York, Springer-Verlag New York, Inc, 1972, p 212
28. Re RN: The cellular biology of angiotensin: Paracrine, autocrine and intracrine actions in cardiovascular tissues. J Mot Cell Cardiol 1989;21(suppl V):63-69
29. Naftilan AJ, Gilliland GK, Eldridge CS, Kraft AS: Induction of the proto-oncogene c-jun by angiotensin II. Mol Cell Biol 1990;10:5536-5540
30. Naftilan AJ, Pratt RE, Dzau VJ: Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-1424
31. Powell JS, Qozel J-P, Muller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR: Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-188
32. Tarazi RC, Zanchetti A: Prospectives for angiotensin converting enzyme inhibition in heart diseases. J Hypertens 1985;3(suppl): S99-S103
33. Fernandez LA, Twiclder J, Mead A: Neovascularization produced by angiotensin II. J Lab Clin Med 1985;105:141-145
34. Deinum J, Derkx FHM, Danser AHJ, Schalekamp MADH: Identification and quantification of renin and prorenin in the bovine eye. Endocrinology 1990;126:1673-1682
35. Mendelsohn FAO: Evidence for the local occurrence of Ang II in rat kidney and its modulation by dietary sodium intake and converting enzyme blockade. Clin Sci 1979;57:173-179
36. Miyamori I, Brown MJ, Dollery CT: Single-dose captopril administration in DOCA/salt rats: Reduction of hypotensive effect by indomethacin. Clin Exp Hypertens [A) 1980;2: 935-945
37. Marks ES, Bing RF, Thurston H, Swales JD; Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14 225): The role of factors other than renin-angiotensin blockade in the rat. Clin Sci 1980 58:1-6
38. Abe K, Ito T, Sato M, Haruyama T, Sato K, Omata K, Hiwatari M, Sakurai Y, Imai Y, Yoshinaga K: Role of prostaglandin in the anti hypertensive mechanism of captopril in low renin hypertension, Clin Sci 1980;59;141s-144s
39. Man In’t Veld AJ, Schicht IM, Derkx FHM, De Bruyn JHB, Schalekamp MADH: Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects. Br Med J 1980;230:288-296
40. ErdOs EG: Angiotensin I converting enzyme and the changes in our concepts through the years: Lewis K Dahl Memorial Lecture. Hypertension 1990;16:363-370
41. Mullins JJ, Peters J, Ganten D: Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990;344:541-544
42. Itoh H, Nakao K, Mukqyama M, Yamada T, Hosoda K, Shirakami G, Morii N, Sugawara A, Saito Y, Shiono S, Arai H, Yoshida I, Imura H: Chronic blockade of endogenous a trial natriuretic polypeptide (ANP) by monoclonal antibody against ANP accelerates the development of hypertension in spontaneously hypertensive and deoxycorticosterone acctate-salt-hypenensive rats. J Clin Invest 1989;84:145-154
43. Cherry PD, Furchgott RF, Zawadzki JV, Jothianandan D: Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci USA 1982;79:2106-2110
44. Vane JR, AnggSrd EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36
45. Vanhoutte PM: Endothelium and control of vascular function: Slate of the art lecture. Hypertension 1989;13:658-667
46. Lahera V, Salom MG, Fiksen-Olsen MJ, Romero JC: Mediation of endothelium derived relaxing factor in renal response to bradykinin and acetylcholine (abstract). J Hypertens 1990;8(suppl):S30
47. Regoli D: Pharmacology of bradykinin and related kinins. Adv Exp Med Biol 1983;156:569-584
48. Regoli D, Rhaleb N-E, Dion S, Drapeau G: New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization. Trends Pharmacol Sci 1990;11:156-161
49. Stewart JM, Vavrek RJ: Bradykinin competitive antagonists for classical kinin systems, in Greenbaum LM, Margolius HS (eds): Kinins IV, Advances in Experimental Medicine and Biology. New York, Plenum Publishing Corp, 1986, p 537
50. Beierwaltes WH, Carretero OA, Scicli AG, Vavrek RJ, Stewart JM: Competitive analog antagonists of bradykinin in the canine hindlimb. Proc Soc Exp Biol Med 1987;186:79-83
51. Berg T, Carretero OA, Scicli AG, Tilley B, Stewart JM: Role of kinin in regulation of rat submandibular gland blood flow. Hypertension 1989;14:73-80
52. Seino M, Carretero OA, Albertini R, Scicli AG: Kinins in regulation of uteroplacental blood flow in the pregnant rabbit. Am J Physio! 1982;242:H142-H147
53. Roman RJ, Ka Id unski ML, Scicli AG, Carretero OA: Influence of kinins and angiotensin II on the regulation of papillary blood flow. Am 1 Physiol 1988;255:F690-F698
54. Seino M, Abe K, Nushiro N, Omata K, Kasai Y, Yoshinaga K: Effects of a competitive antagonist of bradykinin on blood pressure and renal blood flow in anesthetized rats. J Hypertens 1988;6:867-871
55. Orstavik TB, Carretero OA. Johansen L, Scicli AG: Role of kallikrein in the hypotensive effect of captopril after sympathetic stimulation of the rat submandibular gland. Cirt Res 1982;51:385-390
56. Scicli AG, 0rstavik TB, Rabito SF, Murray RD, Carretero OA: Blood kinins after sympathetic nerve stimulation of the rat submandibular gland. Hypertension 1983;5(suppl I): M01-I-106
57. Beierwaltes WH, Carretero OA, Scicli AG: Renal hemodynamics in response to a kinin analogue antagonist. Am J Physiol 1988;255:F408-F414
58. Roman RJ, Smits C: Laser-Doppler determination of papillary blood flow in young and adult rats. Am J Physiol 1986;251:F115-F124
59. Madeddu P, Glorioso N, Soro A, Manunta P, Troffa C, Tonolo G, Grazia Melis M, Pazzola A: Effect of a kinin antagonist on renal function and haemodynamics during alterations in sodium balance in conscious normotensive rats. Clin Sci 1990;78:165-168
60. Zimmerman BG, Raich PC, Vavrek RJ, Stewart JM; Bradykinin contribution to renal blood flow: Effect of angiotensin converting enzyme inhibitor in the conscious sodium-restricted dog. Cirt Res 1990;66:234-240
61. Nakagawa M, Stewart JM, VsvTek RJ, Nasjletti A: Effects of a kinin antagonist on renal function in rats. Am J Physiol 1990;258:F643-F648
62. Kauker ML: Bradykinin action on the efflux of luminal “Na in the rat nephron. J Pharmacol Exp Ther 1980;214:119-123
63. Kauker ML: Kallidin effect on renal tubular function in meclofenamate-and vehicle-pretreated rats. Proc Soc Exp Biol Med 1990;193:60-64
64. Kauker ML, Gisi PJ, Zawada ET: Renal kinins and sodium transport: Influence of a bradykinin receptor antagonist (BKRA) (abstract). FASEB J 1990;4:A990
65. Ura N, Carretero OA, Erdfls EG: Role of renal endopepti-dase 24.11 in kinin metabolism in vitro and in vivo. Kidney Ini 1987;32:507-513
66. Sybertz EJ, Chiu PJS, Vemulapalli S, Watkins R, Haslanger MF: Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826: An orally active neutral metal-loendopeptidase inhibitor. Hypertension 1990;15:152-161
67. Pollock DM, Butterfield ML, Ader JL, Arendshorst WJ: Dissociation of urinary kallikrein activity and salt and water excretion in the ml. Am J Physiol 1986;250:F1082-F1089
68. Nasjletti A, McGiff JC, Colina-Chourio J: Interrelations of The renal kallikrein-kinin system and renal prostaglandins in ihe conscious rat: Influence of mineralocortiooids. Circ Res 1978;43:799-807
69. Marin Grez M: The influence of antibodies against bradykinin on isotonic saline diuresis in Ihe rat: Evidence for kinin involvement in renal function, Pflugen Arch 1974;350: 231-239
70. Tomiyama H, Scicii AG, Scicii GM, Carretero OA: Renal effects of Fab fragments of kinin antagonists on deotnycorticosterone acetate-salt-treated rats. Hypertension 1990;15: 413-414
71. Scicii AG, Mindroiu T, Scicii G, Carretero OA: Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J Lab Clin Med 1982;100:81-93
72. Bonner G, Preis S, Schunk U, Toussaint C, Kaufmann W: Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990;15(suppl 6):S46-S56
73. Salgado MCO, Rabito SF, Carretero OA: Blood kinin in one-kidney, one clip hypertensive rats. Hypertension 1986; 8(suppl I):I-110-1-113
74. Sacd GM, Carretero OA, MacDonald RJ, Scicii AG: Kallikrein messenger RNA in rat arteries and veins. Circ Res 1990;67:510-516
75. Oza NB, Schwartz JH, Goud HD, Levinsky NG: Rat aortic smooth muscle cells in culture express kallikrein, kininogen, and bradykininasc activity, J Clin Invest 1990;85:597-600
76. Benetos A, Gavras I, Gavras H: Hypertensive effect of a bradykinin antagonist in normotensive rats. Hypertension 1986;8:1089-1092
77. Carbonell LF, Carretero OA, Madeddu P, Scicii AG: Effects of a kinin antagonist on mean blood pressure. Hypertension 1988;11(suppl l):I-84-I-88
78. Staszewska-Barczak J, Vane JR: The release of catecholamines from the adrenal medulla by peptides. Br J Pharmacol Chemother 1967;30:655-667
79. Beierwaltes WH, Carretero OA: Kallikrein and kinins independently stimulate renin release from isolated rat glomeruli. Adv Exp Med Biol 1986;198:265-272
80. Johnson AR, Erdos EG; Release of histamine from mast cells by vasoactive peptides. Proc Soc Exp BioI Med 1973; 142: 1252-1256
81. Terragno NA, Lonigro AJ, Malik KU, McGiff JC; The relationship of the renal vasodilator action of bradykinin to the release of a prostaglandin E-like substance. Experientia 1972;28:437-439
82. Waeber B, Aubert JF, Nussberger J, Vavrek R, Stewart JM, Brunner HR: Influence of bradykinin on blood pressure regulation of spontaneously hypertensive rats maintained on different sodium intakes, Clin Exp Pharmacol Physiol 1987; 14:659-664
83. Carretero OA, Scicii AG: The renal kallikrein-kinin system in human and in experimental hypertension. Klin Wochenschr 1978;56(suppl I):113-125
84. Williams RR, Hunt SC, Hasstedt SJ, Berry TD, Wu LL, Barlow GK, Stults BM, Kuida H: Definition of genetic factors in hypertension: A search for major genes, polygenes, and homogeneous subtypes. J Cardiovasc Pharmacol 1988; 12: S7-S20
85. Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, Kuida H, Williams RR: A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 1989;13:3-8
86. Zinner SH, Margolius HS, Rosner B, Keiser HR, Kass EH: Familial aggregation of urinary kallikrein concentration in childhood: Relation to blood pressure, race and urinary electrolytes. Am J Epidemiol 1976;104:124-132
87. Zinner SH, Margolius HS, Rosner B, Kass EH: Stability of blood pressure rank and urinary kallikrein concentration in childhood: An eight-year follow-up. Circulation 1978;58: 908-915
88. Carretero OA, Amin VM, Ocholik T, Scicii AG, Koch J: Urinary kallikrein in rats bred for their susceptibility and resistance to the hypertensive effect of salt; A new radioimmunoassay for its direct determination. Circ Res 1978;42: 727-731
89. Carretero OA, Polomski C, Hampton A, Scicii AG: Urinary kallikrein, plasma renin and aldosterone in New Zealand genetically hypertensive (GH) rats. Clin Exp Pharmacol Physiol 1976;3(suppl):55-59
90. Carretero OA, Scicii AG, Piwonska A, Koch J: Urinary kallikrein in rats bred for susceptibility and resistance to the hypertensive effect of salt and in New Zealand genetically hypertensive rats. Mayo Clin Proc 1977;52:465-467
91. Keiser HR, Geller RG, Margolius HS, Pisano JJ: Urinary kallikrein in hypertensive animal models. Fed Proc 1976;35: 199-202
92. Holland OB, Chud JM, Braunstein H: Urinary kallikrein excretion in essential and mineralocorticoid hypertension. JClin Invest 1980;65:347-356
93. Margolius HS, Horwitz D, Geller RG, Alexander RW, Gill JR Jr, Pisano JJ, Keiser HR: Urinary kallikrein excretion in normal man: Relationships to sodium intake and sodium-retaining steroids. Circ Res 1974;35:812-818
94. Seino M, Abe K, Otsuka Y, Saito T, Irokawa N, Yasujima M, Ciba S, Yoshinaga K: Urinary kallikrein excretion and sodium metabolism in hypertensive patients. Tohoku J Exp Med 1975;116:359-367
95. Sustarsic DL, McPartland RP, Rapp JP, SchlagerG, Tan SY: Urinary kallikrein and urinary prostaglandin E; in genetically hypertensive mice, Proc Soc Exp Biol Med 1980;163:193-199
96. Woodley-Miller C, Chao J, Qiao L: Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J Hypertens 1989;7:865-871
97. Pravenec M, Kfen V, KuneS J, Scicii AG, Carretero OA, Simonet L, Kurtz TW; Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 1991;17: 242-246
98. Carretero OA, Oza NB, Scicii AG, Schork A: Renal tissue kallikrein, plasma renin and plasma aldosterone in renal hypertension, Acta Physiol Latinoam 1974;24:448-452
99. Shkhvatsabaya IK, Nekrasova AA, Chernova NA, Khukharev W: Kinin system of the kidneys in pathogenesis of hypertensive disease (in Russian). Ter Arkh 1973;45:71-77
100. Carretero OA, Kuk P, Piwonska S, Houle JA, Marin-GrezM: Role of the renin angiotensin system in the pathogenesis of severe hypertension in rats, Cirv Res 1971;29:654-663
101. Marks ES, Bing RF, Thurston H, Swales JD: Vasodepressor property of the converting enzyme inhibitor captopril (SO 14 225): The role of factors other than renin-angiotensin blockade in the rat. Clin Sci 1980;58:1-6
102. Qappison BH, Anderson WP, Johnston Cl: Role of the kallikrein-kinin system in the renal effects of angiotensin-converting enzyme inhibition in anaesthetized dogs. Clin Exp Pharmacol Physiol 1981;8:509-513
103. McCaa RE: Studies in vivo with angiotensin I converting enzyme (kininase II) inhibitors. Fed Proc 1979;38:2783-2787
104. Nasjletti A, Colina-Chourio J, McGiff JC: Disappearance of bradykinin in Ihe renal circulation of dogs; Effects of kininase inhibition. Circ Res 1975;37:59-65
105. Vinci JM, Horwitz D, Zusman RM, Pisano JJ, Catt KJ, Keiser HR: The effect of converting enzyme inhibition with SQ20.881 on plasma and urinary kinins, prostaglandin E and angiotensin II in hypertensive man. Hypertension 1979; 1: 416-426
106. Overlack A, Stumpe KO, Heck I, Ressel C, Kuhnert M, Kriick F: Identification of angiotensin II-and kinin-dependent mechanisms in essential hypertension, in Philipp T, Distler A (eds): Hypertension: Mechanisms and Management. Berlin, Springer-Veriag, 1980, p 183
107. Carretero OA, Miyazaki S, Scicti AG: Role of kinins in the acute anti hypertensive effect of the converting enzyme inhibitor, captopril. Hypertension 1981;3:18-22
108. Carretero OA, 0rstavik TB, Rabito SF, Scicli AG: Interference of converting enzyme inhibitors with the kallikrein-kinin system. Clin Exp Hypertens (A I 1983;5:1277-1285
109. Carretero OA, Scicli AG, Maitra SR: Role of kinins in the pharmacological effects of converting enzyme inhibitors, in Horoviiz ZP (ed): Angiotensin Convening Enzyme Inhibitors; Mechanisms of Action. Baltimore, Md, Urban & Schwarzen-berg, 1981, p 105
110. Benetos A, Gavras H, Stewart JM, Vavrek RJ, Hatinoglou S, Gavras I: Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension 1986;8: 971-974
111. Waeber B, Aubert JF, Fluckiger JP, Nussberger J, Vavrek RJ, Stewart JM, Brunner HR: Role of endogenous bradykinin in blood pressure control of conscious rats. Kidney Int Suppt 1988;26:S63-S68
112. CarbonelI LF, Carretero OA, Stewart JM, Scicli AG: Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 1988; 11: 239-243
113. Pontieri V, Lopes OU, Ferreira SH: Hypotensive effect of captopril: Role of bradykinin and prosta gland in like substances. Hypertension 1990;15(suppl l):I-55-I-58
114. Erdos EG, Skidgel RA: Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEBJ 1989;3:145-151
115. Schwartz J-C, Gros C, Lecomte J-M, Bralet J: Enkephalinase (EC 3.4.24.11) inhibitors: Protection of endogenous ANF against inactivation and potential therapeutic applications. Life Sci 1990, 47:1279-1297
116. Ishida H, Scidi AG, Carretero OA: Role of angiotensin converting enzyme and other peptidases in in vivo metabolism of kinins. Hypertension 1989;14:322-327
117. Smits GJ, McGraw DE, Trapani AJ: Interaction of ANP and bradykinin during endopeptidase 24.11 inhibition: Renal effects. Am J Physiol 1990;258:F1417-F1424
118. Samuels GMR, Barclay PL, Peters CJ, Ellis P: Atriopepti-dase inhibitors, a novel class of drug that raises levels of endogenous atrial natriuretic factor: The preclinical pharmacology of UK-69, 578 (abstract), J Am Coll Cardiol 1989; 13: 75A
119. Richards M, Espiner E, Frampton C, Ikram H, Yandle T, Sopwith M, Cussans N: Inhibition of endopeptidase EC24.11 in humans: Renal and endocrine effects. Hypertension 1990; 16:269-276
120. Kosoglou T, Herron JM, Chen R, Given BD, Sybertz EJ, Affrime MB: Antihypertensive effect of the atriopeptidase inhibitor SCH 34826 in essential hypertension (abstract). Circulation 1990;82(suppl III):III-554